What Is Breast Implant Illness?
Breast implant illness (BII) describes a pattern of systemic symptoms that some women with breast implants — both textured and smooth — report and attribute to their implants. Common symptoms include severe chronic fatigue, joint and muscle pain throughout the body, cognitive impairment (brain fog, difficulty concentrating), hair loss, skin rashes, dry eyes and mouth, anxiety and depression, and autoimmune-like conditions such as Hashimoto's thyroiditis or lupus-like presentations. BII symptoms can begin months or years after implant placement and often resolve or improve after explantation, though not always completely.
BII vs. BIA-ALCL — A Critical Legal Distinction
BII and BIA-ALCL are completely different conditions with different legal trajectories. BIA-ALCL is a confirmed lymphoma with a definitive causal link to textured implants — particularly Allergan BIOCELL — that is recognized by the FDA, WHO, and the medical community. BIA-ALCL cases have strong scientific causation foundations and the clearest path to compensation in MDL 2921. BII, by contrast, is not a single formally recognized medical diagnosis by the FDA or NIH as of 2026. The constellation of symptoms has not been attributed to a single disease mechanism, and the causal link between implants and systemic symptoms remains scientifically contested. This does not mean BII claims have no merit — women are genuinely suffering — but it means BII claims face greater legal challenges on causation and require more individualized expert testimony. Women with BII and Allergan BIOCELL implants should still consult an attorney, as the MDL includes BII claimants and litigation strategy continues to evolve.
Who Qualifies for a BII Claim in MDL 2921?
To have a BII claim evaluated in MDL 2921, you generally must have: Allergan BIOCELL textured breast implants placed before the July 2019 recall; documented systemic symptoms consistent with BII that your physicians have evaluated; and evidence that your symptoms are not better explained by an independent medical condition. Explantation that resulted in significant symptom improvement can be a strong supporting factor. BII claims that can be tied specifically to BIOCELL's macro-texture (on the theory that the inflammatory response it induces is greater than smooth implants) have a stronger litigation posture than generic BII claims against all implant manufacturers. An attorney will evaluate your symptom documentation, medical history, and explant outcome to advise on the strength of a BII claim.
Frequently Asked Questions
Related Pages
BIA-ALCL is not breast cancer — it is a T-cell lymphoma of the immune system that develops in the fluid or capsule surrounding Allergan BIOCELL textured implants. It is often curable when caught early, but advanced stages require chemotherapy and carry serious health consequences.
Learn moreBIA-ALCL staging — from Stage IA (confined to seroma fluid) through Stage IV (distant metastases) — is the single most important factor in determining the value of an Allergan breast implant lawsuit. Early-stage cases are curable; advanced stages require chemotherapy and carry worse prognosis and significantly higher compensation.
Learn moreThe July 24, 2019 Allergan BIOCELL recall was the largest breast implant recall in FDA history. It covered 33+ product lines after the FDA determined BIOCELL recipients faced a 6x elevated risk of BIA-ALCL lymphoma. French regulators had recalled the same product a year earlier in 2018.
Learn moreThe Allergan Natrelle 410 Highly Cohesive Anatomically Shaped implant was the most widely used recalled product and is at the center of MDL 2921. McGhan textured implants — an earlier Allergan brand — are also covered by the July 2019 recall. If you received either product, you may have a claim.
Learn moreWomen who received Allergan BIOCELL textured implants or tissue expanders as part of post-mastectomy breast reconstruction after breast cancer are a distinct and especially sympathetic plaintiff class in MDL 2921. They fought breast cancer once — and Allergan's recalled product put them at risk of a second cancer.
Learn moreThe FDA does not recommend prophylactic removal of Allergan BIOCELL implants for asymptomatic patients. However, women who chose explantation after the recall may have legal claims for surgery costs. Women with BIA-ALCL symptoms require immediate medical evaluation — not observation.
Learn moreNo global Allergan BIOCELL settlement has been announced as of February 2026. The October 2026 bellwether trial will drive settlement negotiations. Based on comparable medical device MDLs, BIA-ALCL Stage IA cases may settle in the $50,000–$300,000 range; Stage IV cases may command $1,000,000–$3,000,000 or more.
Learn moreThe statute of limitations for Allergan BIOCELL claims is typically 2 to 3 years from discovery — meaning from BIA-ALCL diagnosis, not from implant placement or recall date. Discovery rule protections apply in most states. Consult an attorney immediately — deadlines are strict and MDL tolling is not automatic.
Learn moreYou may qualify if you received Allergan BIOCELL textured implants (for augmentation or reconstruction), were diagnosed with BIA-ALCL, or had your implants removed due to the recall. You do not need a cancer diagnosis to file. Implants already removed do not disqualify you.
Learn moreAllergan Breast Implant Lawsuit Lawsuit
Allergan (now owned by AbbVie) manufactured BIOCELL textured breast implants — including the widely used Natrelle 410 — that were found to cause breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare but serious T-cell lymphoma of the immune system. The FDA determined that women with Allergan BIOCELL implants were approximately six times more likely to develop BIA-ALCL than women with implants from other manufacturers. On July 24, 2019, Allergan initiated a worldwide recall of all BIOCELL textured breast implants and tissue expanders. As of June 2023, the FDA had received 1,264 BIA-ALCL reports globally, with 1,079 — representing 85% of all cases — involving Allergan implants. Sixty-three deaths have been reported, with 37 linked to Allergan products. MDL 2921, In re Allergan BIOCELL Textured Breast Implant Products Liability Litigation, is pending before Judge Michael Martinotti in the District of New Jersey with approximately 1,400 cases. The first bellwether trial is scheduled for October 2026. Women who received Allergan BIOCELL textured implants, were diagnosed with BIA-ALCL, or underwent implant removal due to the recall may have viable legal claims.
View full case overview